Roche's Daily Breast Cancer Pill Faces High-Stakes US FDA Review After Slashing Relapse Risk by 30%
Swiss drugmaker Roche is seeking US FDA approval for its once-daily oral breast cancer therapy following clinical trial data showing a 30% reduction in disease recurrence.
By Gaurav Sen•6h ago•2 min read